Axsome Therapeutics (AXSM) Gross Margin (2022 - 2026)

Axsome Therapeutics has reported Gross Margin for 5 years, with the latest figure at 92.3% in Q1 2026.

• Quarterly Gross Margin rose 36.0% year-over-year to 92.3% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 92.6% (up 432.0% YoY) and the FY2025 annual result came in at 92.56%, up 120.0% from the prior year.
• Gross Margin eased to 92.3% in Q1 2026 per AXSM's latest filing, from 93.71% in the prior quarter.
• Over five years, Gross Margin peaked at 93.71% in Q4 2025 and troughed at 2002.8% in Q4 2024.
• A 5-year average of 39.87% and a median of 90.9% in 2025 frame the typical range for Gross Margin.
• The sharpest annual moves came in 2024 and 2025: Gross Margin tumbled 209249 bps in 2024, then surged 209651 bps in 2025.
• Over 5 years, Gross Margin stood at 90.6% in 2022, then fell by 1 bps to 89.69% in 2023, then tumbled by 2333 bps to 2002.8% in 2024, then jumped by 105 bps to 93.71% in 2025, then decreased by 2 bps to 92.3% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 92.3%, 93.71%, and 93.03% for Q1 2026, Q4 2025, and Q3 2025 respectively.